中晚期非小细胞肺癌同步放化疗联合靶向治疗临床效果观察.docVIP

中晚期非小细胞肺癌同步放化疗联合靶向治疗临床效果观 三峡大学仁和医院 443000 作者简介：杨全军(出生于1973年12月，男，土家族)籍贯：湖北省宜昌市; 学历：本科；科室：肿瘤科；研宄方向：肺癌 【摘要】目的考察同步放化疗联合靶向治疗屮晚期非小细胞肺癌的临床效果。 方法回顾性选择从2007年10月~2012年11月期间在我院进行诊断治疗的屮晚 期非小细胞肺癌患者124例为研宂对象，将采用同步放化疗联合靶向治疗的64 例患者定义为实验组，将单纯采用同步放化疗治疗的60例患者定义为对照组， 经相应治疗后随访6?35.7个月，比较两组患者的临床疗效、生存状况以及不良 反应情况。结果实验组客观缓解率与疾病控制率分别为81.25%与90.63%，均优 于对照组80.00%与88.33%,但差异不明显；实验组CR 24例(37.50%)优于对 照组16例(26.67%),差异明显(Plt;0.05)；实验组中位PFS与中位OS分别为 14.8个月与21.3个月，均远远高于对照组8.6个月与10.5个月，差异明显；实 验组六个月、一年与两年的生存率分别为81%、67%、34%,均明显高于对照组 72%、42%、21%,差异显著(Plt;0.01)；实验组不良反应放射性肺炎、胃肠道 反应、腹泻以及骨髓抑制发生率较低。结论同步放化疗联合靶向治疗屮晚期非 小细胞肺癌能提高患者完全缓解率，减少不良反应的发生，延长生存时间。 【关键词】屮晚期非小细胞肺癌；同步放化疗；靶向治疗；控制率 【屮图分类号】R4【文献标识码】A【文章编号】1001-5213(2016)08-0297-02 [Abstract] Objective To investigate the clinical effect of concurrent chemotherapy combined with targeted therapy in the treatment of advanced non-small cell lung cancer. Methods a retrospective selection from October 2007 ?2012 year in November in our hospital for diagnosis and treatment in patients with advanced non-small cell lung cancer in 124 cases as the research object, will use the same step chemotherapy combined with targeted 64 patients the definition of treatment for the experimental group, only 60 cases of patients with defined chemoradiation therapy as the control group, after treatment were followed up for 6?35.7 months, compared with two groups of curative effect, survival and adverse reactions. Results the experimental group objective response rate and disease control rate were 81.25% and 90.63%, were 80% and 88.33% than the control group, but the difference is not obvious; the experimental group CR 24 cases (37.50%) than the control group of 16 cases (26.67%), significant difference (Plt;0.05); experimental group median PFS and median OS was 14.8 months And 21.3 months, are far higher than the control group of 8.6 months and 10.5 months, significant difference. In the experimental group, six months, one year and two years survival rates were 81%, 67%, 34%, significantly